Segment information

12 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure

SEGMENT INFORMATION

Product Sales

We operate in one business segment, which primarily focuses on the discovery, development and commercialization of innovative medicines in areas of unmet medical need. All products are included in one segment, because the majority of our products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

Product sales consist of the following (in millions):

	Year Ended December 31,
	2014		2013		2012
Antiviral products:
Sovaldi	$	10,283	$	139	$	—
Atripla	3,470		3,648		3,574
Truvada	3,340		3,136		3,181
Harvoni	2,127		—		—
Complera/Eviplera	1,228		810		342
Stribild	1,197		539		58
Viread	1,058		959		849
Other antiviral	88		111		138
Total antiviral products	22,791		9,342		8,142
Other products:
Letairis	595		520		410
Ranexa	510		449		373
AmBisome	388		352		346
Zydelig	23		—		—
Other	167		141		127
Total product sales	$	24,474	$	10,804	$	9,398

The following table summarizes total revenues from external customers and collaboration partners by geographic region (in millions). Product sales and product-related contract revenue are attributed to regions based on ship-to location. Royalty and non-product related contract revenue are attributed to regions based on the location of the collaboration partner.

	Year Ended December 31,
	2014		2013		2012
Revenues:
United States	$	18,182	$	6,695	$	5,592
Europe	5,442		3,614		3,333
Other countries	1,266		893		777
Total revenues	$	24,890	$	11,202	$	9,702

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):

	Year Ended December 31,
	2014		2013		2012
AmerisourceBergen Corp.	25	%	13	%	11	%
McKesson Corp.	24	%	16	%	16	%
Cardinal Health, Inc.	14	%	17	%	19	%

Long-lived Assets

At December 31, 2014, the net book value of our property, plant and equipment (less office and computer equipment) in the United States, Ireland and Canada was $1.3 billion, $127 million, and $86 million, respectively. At December 31, 2013, the net book value of our property, plant and equipment (less office and computer equipment) in the United States, Ireland and Canada was $883 million, $118 million and $55 million, respectively.